98%
921
2 minutes
20
Vasoactive intestinal peptide (VIP) is a neuropeptide that exerts various vascular and cardioprotective functions and regulates immune function and inflammatory response at multiple levels. However, its role in inflammatory cardiovascular disorders is largely unknown. Myocarditis and atherosclerosis are two inflammatory and autoimmune cardiovascular diseases that cause important adverse circulatory events. In this study, we investigate the therapeutic effects of VIP in various well-established preclinical models of experimental autoimmune myocarditis and atherosclerosis. Intraperitoneal injection of VIP during the effector phase of experimental autoimmune myocarditis in susceptible BALB/c mice significantly reduced its prevalence, ameliorated signs of heart hypertrophy and injury, attenuated myocardial inflammatory infiltration, and avoided subsequent profibrotic cardiac remodeling. This effect was accompanied by a reduction of Th17-driven cardiomyogenic responses in peripheral lymphoid organs and in the levels of myocardial autoantibodies. In contrast, acute and chronic atherosclerosis was induced in apolipoprotein E-deficient mice fed a hyperlipidemic diet and subjected to partial carotid ligation. Systemic VIP treatment reduced the number and size of atherosclerotic plaques in carotid, aorta, and sinus in hypercholesterolemic mice. VIP reduced Th1-driven inflammatory responses and increased regulatory T cells in atherosclerotic arteries and their draining lymph nodes. VIP also regulated cholesterol efflux in macrophages and reduced the formation of foam cells and their presence in atherosclerotic plaques. Finally, VIP inhibited proliferation and migration of smooth muscle cells and neointima formation in a mouse model of complete carotid ligation. These findings encourage further studies aimed to assess whether VIP can be used as a pharmaceutical agent to treat heart inflammation and atherosclerosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4049/jimmunol.1800122 | DOI Listing |
World J Hepatol
August 2025
Department of Hospital Medicine, Hartford Hospital, Hartford, CT 06102, United States.
Hepatitis C virus (HCV) infection has been increasingly associated with cardiovascular complications, particularly atherosclerosis and cardiomyopathy, in addition to its primary hepatic effects. Studies indicate a higher prevalence of carotid atherosclerosis in patients with chronic hepatitis C infection, with viral load and steatosis emerging as independent risk factors. HCV-related atherosclerosis appears to develop through complex processes involving endothelial dysfunction, inflammation, oxidative stress, and immune dysregulation.
View Article and Find Full Text PDFJAMA Cardiol
August 2025
Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Importance: Clonal hematopoiesis of indeterminate potential (CHIP) is the age-related clonal expansion of hematopoietic stem cells with leukemia-associated mutations. Certain CHIP mutations promote atherosclerosis and heart failure through immune-related pathways.
Objective: To test whether CHIP is associated with the development of myocarditis and pericarditis.
Rev Inst Med Trop Sao Paulo
August 2025
Universidade Federal do Maranhão, Hospital Universitário, São Luís, Maranhão, Brazil.
Chikungunya virus (CHIKV) is globally distributed and transmitted by Aedes mosquitoes, with a mortality rate of 0.8/1,000 cases. The heart is the second most affected organ, with the osteoarticular system being the first.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pyroptosis is an inflammatory form of programmed cell death, distinct from apoptosis, necroptosis, and ferroptosis, and is primarily mediated by gasdermin proteins and inflammatory caspases. Recent advances highlight the central role of pyroptosis in the pathogenesis and progression of a spectrum of cardiovascular diseases, including myocardial infarction, myocarditis, heart failure, atherosclerosis, hypertension, and cardiac arrhythmias. Activation of inflammasomes and the subsequent cleavage of gasdermins drive cell membrane pore formation, leading to the release of interleukin-1β (IL-1β), interleukin-18 (IL-18), and other pro-inflammatory mediators, amplifying tissue injury and sterile inflammation.
View Article and Find Full Text PDFFront Immunol
August 2025
Department of Cardiovascular Diseases, First Hospital of Jilin University, Jilin University, Changchun, China.
The emergence of immune checkpoint inhibitors (ICIs) have provided a new perspective for cancer immunotherapy. Immune checkpoint inhibitors significantly improve the survival prognosis of patients with various advanced cancers by inhibiting immune checkpoint molecules, thereby releasing the suppression of T cells by tumor microenvironment, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Immune checkpoint inhibitor (ICI) therapy, while effective, gives rise to distinct immune-related adverse events (irAEs), including cardiovascular toxicities, necessitating focused research efforts to better understand and address these specific complications.
View Article and Find Full Text PDF